Abstract:The pathobiology of MAFLD is such a big puzzle, and many of the metabolic and other health consequences of the disease are not yet fully elucidated. In their review on "Pathobiology of metabolic-associated fatty liver disease," Fouda and colleagues update the current evidence on the disease characteristics. The prevalence of MAFLD has reached epidemic proportions in children and young adults in the recent years, with figures reaching as high as 15% owing to the global obesity pandemic. Vespoli and colleagues in their review "MAFLD in childhood and adolescence" portray the latest updates and new emerging therapies for pediatric MAFLD. Gofton and colleagues update the association between metabolically unhealthy visceral adiposity and MAFLD in individuals with "normal body weight" in their review "Lean MAFLD." The pathobiological link between dyslipidemia and MAFLD is elaborated by Anwar and colleagues with the therapeutic algorithms. Ren and colleagues summarize evidence surrounding cardiovascular disease and MAFLD and analyze management strategies focusing on prevention of cardiovascular disease in MAFLD. Another important review by Kapoor and Kalra discusses the hot topic of diabetes and MAFLD and portrays the latest management strategies for both diseases. Barber and colleagues thoroughly review the gut-liver axis in the context of gut dysbiosis in MAFLD. Sarcopenia and MAFLD is the theme of the review by Bali and colleagues. This article emphasizes the importance of early identification of sarcopenia in patients with MAFLD and vice versa. Obstructive sleep apnea and MAFLD are often underdiagnosed and inadequately managed. Preshy and Brown in their review highlight the association between these common disorders to enhance the global awareness with updated evaluation and management strategies in their review. Mandato and colleagues review current literature on pregnancy and MAFLD and update the best clinical approach in their article. The interlink between polycystic ovary syndrome and MAFLD, their coexistence, diagnosis, and current management strategies are critically apprised by Vidal-Cevallos and colleagues in their review. Venkatesan and Haroon successively provide more important evidence for the clinical management of MAFLD with additional focus on minority groups and currently available therapies.

Underlying Mechanisms behind the Brain-Gut-Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update

Metabolic-Associated Fatty Liver Disease: The Influence of Oxidative Stress, Inflammation, Mitochondrial Dysfunctions, and the Role of Polyphenols

New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut-Liver-Heart Crosstalk

Detangling the interrelations between MAFLD, insulin resistance, and key hormones

Current insights into the interplay between gut microbiota-derived metabolites and metabolic-associated fatty liver disease

Role of gut-liver axis and glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease

MAFLD as part of systemic metabolic dysregulation

Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact

Interplay between metabolic dysfunction-associated fatty liver disease and chronic kidney disease: Epidemiology, pathophysiologic mechanisms, and treatment considerations

Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies

Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways

Metabolic-Associated Fatty Liver Disease and the Gut Microbiota

Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease

The Many Faces of Metabolic Dysfunction-Associated Fatty Liver Disease Treatment: From the Mediterranean Diet to Fecal Microbiota Transplantation

Metabolic-Associated Fatty Liver Disease: A Disastrous Human Health Challenge

From Liver to Brain: How MAFLD/MASLD Impacts Cognitive Function

Pathophysiological Molecular Mechanisms of Obesity: A Link between MAFLD and NASH with Cardiovascular Diseases

The microbial metabolome in metabolic-associated fatty liver disease

Gut microbiota in MAFLD: therapeutic and diagnostic implications

Metabolic dysfunction: The silenced connection with fatty liver disease

Molecular mechanisms in the pathogenesis of metabolically associated fatty liver disease